KR960013383A - 항혈전성 및 피브린용해성 치료제와 조합하여 사용되는 치료제로서의 폰 빌레브란트 인자(vWF)-함유 농축물의 용도 - Google Patents
항혈전성 및 피브린용해성 치료제와 조합하여 사용되는 치료제로서의 폰 빌레브란트 인자(vWF)-함유 농축물의 용도 Download PDFInfo
- Publication number
- KR960013383A KR960013383A KR1019950035874A KR19950035874A KR960013383A KR 960013383 A KR960013383 A KR 960013383A KR 1019950035874 A KR1019950035874 A KR 1019950035874A KR 19950035874 A KR19950035874 A KR 19950035874A KR 960013383 A KR960013383 A KR 960013383A
- Authority
- KR
- South Korea
- Prior art keywords
- vwf
- von willebrand
- willebrand factor
- antithrombotic
- combination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hematology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
본 발명은 혈액 항응고제를 치료제로서 단독으로 사용하거나 피브린 용해소와 함께 사용하는 것과 연관하여 폰 빌레브란트 인자(vWF)- 함유 약물의 투여에 관한 것이다. 환자에게 출혈의 위험을 감소시킬 목적으로 항응고제 치료 및 용해 치료와 동시에 또는 이후 투여할 수 있다. 치료하는 동안 바람직한 효과인 항응고 및/또는 피브린 용해를 바람직하지 않은 출혈과 분리시키는 것이 치료 원리로 서술된다.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (3)
- 항혈전제 및/또는 피브린용해제의 투여로 인해 야기되는 출혈과 관련하여 해독제로서 작용하는 제제를 제조하기 위한, 폰 빌레브란트 인자(vWF) 또는 vWF 활성을 갖는 단편의 용도.
- 성분 A로서 항혈전제 및/또는 피브린용해제를 함유하고, 성분 B로서 vWF 또는 vWF 활성을 갖는 단편을 함유하는 약제학적 조성물
- 제 2항에 있어서, 개개 성분이 별개의 단일 투여 형태로 존재하는 약제하적 조성물※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DEP4437544.1 | 1994-10-20 | ||
DE4437544A DE4437544A1 (de) | 1994-10-20 | 1994-10-20 | Einsatz von vWF-enthaltenden Konzentraten als Kombinationstherapie bei Therapie mit Antithrombotika und Fibrinolytika |
Publications (1)
Publication Number | Publication Date |
---|---|
KR960013383A true KR960013383A (ko) | 1996-05-22 |
Family
ID=6531287
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019950035874A KR960013383A (ko) | 1994-10-20 | 1995-10-18 | 항혈전성 및 피브린용해성 치료제와 조합하여 사용되는 치료제로서의 폰 빌레브란트 인자(vWF)-함유 농축물의 용도 |
Country Status (20)
Country | Link |
---|---|
US (1) | US5571784A (ko) |
EP (1) | EP0713881A3 (ko) |
JP (1) | JPH08208504A (ko) |
KR (1) | KR960013383A (ko) |
CN (1) | CN1128168A (ko) |
AU (1) | AU708670B2 (ko) |
CA (1) | CA2160975A1 (ko) |
CZ (1) | CZ287878B6 (ko) |
DE (1) | DE4437544A1 (ko) |
FI (1) | FI954964A (ko) |
HR (1) | HRP950525A2 (ko) |
HU (1) | HU219595B (ko) |
IL (1) | IL115652A (ko) |
NO (1) | NO954175L (ko) |
NZ (1) | NZ280274A (ko) |
PL (1) | PL183182B1 (ko) |
SK (1) | SK129695A3 (ko) |
TW (1) | TW398977B (ko) |
UY (1) | UY24063A1 (ko) |
ZA (1) | ZA958838B (ko) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5772629A (en) * | 1995-10-23 | 1998-06-30 | Localmed, Inc. | Localized intravascular delivery of TFPI for inhibition of restenosis in recanalized blood vessels |
AT405485B (de) * | 1997-05-28 | 1999-08-25 | Immuno Ag | Eine das vwf-propeptid enthaltende pharmazeutische präparation |
AT409335B (de) * | 1998-11-10 | 2002-07-25 | Immuno Ag | Pharmazeutisches präparat enthaltend einen rezeptor-antagonisten zur behandlung von blutgerinnungsstörungen |
US6794412B1 (en) * | 1999-03-11 | 2004-09-21 | Bristol-Myers Squibb Pharma Company | Treatment of thrombosis by combined use of a factor Xa inhibitor and aspirin |
EP1148063A1 (de) * | 2000-04-18 | 2001-10-24 | Octapharma AG | Haemostatisch aktives vWF enthaltendes Präparat und Verfahren zu seiner Herstellung |
JP2003284570A (ja) | 2001-04-25 | 2003-10-07 | Chemo Sero Therapeut Res Inst | フォンビルブラント因子(vWF)切断酵素 |
DE102008032361A1 (de) | 2008-07-10 | 2010-01-21 | Csl Behring Gmbh | Der Einsatz von Faktor VIII und vWF bzw. vWF-enthaltenden Konzentraten zur Therapie der durch Thrombocyten-Inhibitoren induzierte Koagulopathie |
JP5914363B2 (ja) * | 2010-02-16 | 2016-05-11 | ノヴォ ノルディスク アー/エス | 低減されたvwf結合を有する因子viii分子 |
ES2657291T3 (es) | 2013-04-22 | 2018-03-02 | Csl Ltd. | Un complejo covalente de factor de von Willebrand y factor VIII asociado por un puente disulfuro |
TWI580423B (zh) * | 2013-12-24 | 2017-05-01 | 財團法人工業技術研究院 | 緩解或治療痛風之醫藥組合物及其用途 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5198349A (en) * | 1986-01-03 | 1993-03-30 | Genetics Institute, Inc. | Method for producing factor VIII:C and analogs |
US5200510A (en) * | 1987-06-16 | 1993-04-06 | Zymogenetics, Inc. | Method for purifying factor viii:c, von willebrand factor and complexes thereof |
US4774323A (en) * | 1987-06-29 | 1988-09-27 | Rorer Pharmaceutical Corporation | Purification of von Willebrand Factor solutions using gel permeation chromatography |
FR2619314B1 (fr) * | 1987-08-11 | 1990-06-15 | Transgene Sa | Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant |
GB8823480D0 (en) | 1988-10-06 | 1988-11-16 | Ciba Geigy Ag | Antidote |
US5204323B1 (en) | 1988-10-06 | 1995-07-18 | Ciba Geigy Corp | Hirudin antidotal compositions and methods |
FR2673632A1 (fr) * | 1991-03-08 | 1992-09-11 | Lille Transfusion Sanguine | Procede de preparation de concentre de facteur von willebrand humain de tres haute purete, approprie a un usage therapeutique. |
DE4115453A1 (de) | 1991-05-11 | 1992-11-12 | Knoll Ag | Neue wirkstoffkombination |
US5366869A (en) * | 1991-11-08 | 1994-11-22 | Sheldon Goldstein | Multiple coagulation test device and method |
DE4203965A1 (de) * | 1992-02-11 | 1993-08-12 | Max Planck Gesellschaft | Antidot fuer hirudin und synthetische thrombininhibitoren |
ZA942818B (en) * | 1993-04-23 | 1995-01-30 | Bio Technology General Corp | Method of enhancing thrombolysis. |
-
1994
- 1994-10-20 DE DE4437544A patent/DE4437544A1/de not_active Withdrawn
-
1995
- 1995-09-21 EP EP95114846A patent/EP0713881A3/de not_active Withdrawn
- 1995-09-29 TW TW084110150A patent/TW398977B/zh not_active IP Right Cessation
- 1995-10-16 UY UY24063A patent/UY24063A1/es unknown
- 1995-10-18 NZ NZ280274A patent/NZ280274A/en unknown
- 1995-10-18 CZ CZ19952719A patent/CZ287878B6/cs not_active IP Right Cessation
- 1995-10-18 IL IL11565295A patent/IL115652A/xx not_active IP Right Cessation
- 1995-10-18 CN CN95118715A patent/CN1128168A/zh active Pending
- 1995-10-18 HR HRP4437544.1A patent/HRP950525A2/hr not_active Application Discontinuation
- 1995-10-18 US US08/544,867 patent/US5571784A/en not_active Expired - Fee Related
- 1995-10-18 AU AU34304/95A patent/AU708670B2/en not_active Ceased
- 1995-10-18 KR KR1019950035874A patent/KR960013383A/ko not_active Application Discontinuation
- 1995-10-18 SK SK1296-95A patent/SK129695A3/sk unknown
- 1995-10-18 FI FI954964A patent/FI954964A/fi unknown
- 1995-10-19 JP JP7270785A patent/JPH08208504A/ja active Pending
- 1995-10-19 NO NO954175A patent/NO954175L/no not_active Application Discontinuation
- 1995-10-19 PL PL95311031A patent/PL183182B1/pl unknown
- 1995-10-19 CA CA002160975A patent/CA2160975A1/en not_active Abandoned
- 1995-10-19 ZA ZA958838A patent/ZA958838B/xx unknown
- 1995-10-20 HU HU9503031A patent/HU219595B/hu not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
PL183182B1 (pl) | 2002-06-28 |
CZ287878B6 (cs) | 2001-03-14 |
DE4437544A1 (de) | 1996-04-25 |
SK129695A3 (en) | 1996-10-02 |
CZ271995A3 (en) | 1996-05-15 |
HRP950525A2 (en) | 1997-04-30 |
HU219595B (hu) | 2001-05-28 |
ZA958838B (en) | 1996-05-13 |
FI954964A (fi) | 1996-04-21 |
FI954964A0 (fi) | 1995-10-18 |
CN1128168A (zh) | 1996-08-07 |
NO954175D0 (no) | 1995-10-19 |
EP0713881A2 (de) | 1996-05-29 |
IL115652A0 (en) | 1996-01-19 |
AU708670B2 (en) | 1999-08-12 |
HU9503031D0 (en) | 1995-12-28 |
NZ280274A (en) | 1997-01-29 |
PL311031A1 (en) | 1996-04-29 |
EP0713881A3 (de) | 1996-08-21 |
UY24063A1 (es) | 1995-10-24 |
NO954175L (no) | 1996-04-22 |
HUT73762A (en) | 1996-09-30 |
IL115652A (en) | 2000-08-31 |
JPH08208504A (ja) | 1996-08-13 |
US5571784A (en) | 1996-11-05 |
AU3430495A (en) | 1996-05-02 |
TW398977B (en) | 2000-07-21 |
CA2160975A1 (en) | 1996-04-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX9603925A (es) | Combinaciones de anticoagulantes y proteinas activas tromboliticamente, y usos de las mismas. | |
BR9811825A (pt) | Uso de lactobacillus para redução do nìvel de fibrinogênio no sangue | |
DK0913156T3 (da) | Anvendelse af aktiveret protein C til behandling af hyperkoagulationstilstande i forbindelse med sepsis | |
BR0207006A (pt) | Composição farmacêutica, kit, uso de uma preparação de um fator vii ou polipeptìdeo relacionado ao fator vii em combinação com uma preparação de um fator ix ou polipeptìdeo relacionado ao fator ix, uso de uma composição, método para tratar de episódios de hemorragia em um paciente, para reduzir o tempo de coagulação em um paciente, para intensificar a hemostasia em um paciente, para reduzir o número de administrações da proteìna do fator de coagulação necessário para deter a hemorragia e manter a hemostasia em um paciente, para reduzir a quantidade de proteìna do fator de coagulação administrada necessária para deter a hemorragia e manter a hemostasia de um paciente, para prolongar o tempo de lise do coágulo em um paciente, para aumentar a resistência do coágulo em um paciente, e para intensificar a formação de coágulo de fibrina em um paciente | |
ES2160707T3 (es) | Composiciones que comprenden agentes deteriorantes del adn y p53. | |
KR960700742A (ko) | 아토피성질환 치료약(atopic disease remedy) | |
SE8903914D0 (sv) | Oral composition for the treatment of inflammatory bowel diseases | |
KR960013383A (ko) | 항혈전성 및 피브린용해성 치료제와 조합하여 사용되는 치료제로서의 폰 빌레브란트 인자(vWF)-함유 농축물의 용도 | |
ES2119165T3 (es) | Nueva actividad de cofactor anticoagulante. | |
Mannucci | AIDS, hepatitis and hemophilia in the 1980s: memoirs from an insider | |
KR950703353A (ko) | 인슐린-의존적 진성 당뇨병을 예방 또는 치료하기 위한 인터루킨-10의 용도(Use of IL-10 to prevent or treat insulin-dependent diabetes mellitus) | |
DE69133077D1 (de) | Herstellung von ST1435 enthaltenden pharmazeutischen Zusammensetzungen zur topischen Verwendung | |
DE69429576D1 (de) | Dermatansulfatezusammensetzung als antithromotisches mittel | |
JP2003528919A5 (ko) | ||
KR900701309A (ko) | 액체 질소 및 재조합 DNA사람 α인터페론을 혼용하여 생식기우종을 치료하는 방법 | |
KR930019224A (ko) | 유산 위험 치료제 | |
KR960006920A (ko) | 혈액 항응고제에 대한 해독제로서 사용하기에 적합한 약제 및 이의 용도 | |
KR950013519A (ko) | 골절 예방 및 치료용 약제 | |
Schoenenberger et al. | Absence of nitroglycerin-induced heparin resistance in healthy volunteers | |
Engelberg | HEPARIN IN ACUTE MYOCARDIAL INFARCTION—Observations Indicating the Potential Advantages of Using It as the Sole Anticoagulant in Therapy | |
KR900701322A (ko) | 포도필린과 재조합 DNA인간 α인터페론의 배합물로 생식기 우췌를 치료하는 방법 | |
ATE223700T1 (de) | Ramoplaninhaltige neue injizierbare arzneizubereitungen | |
Green | Warfarin-induced factor VII deficiency and the bleeding time | |
DE3579074D1 (de) | Verminderung der toxischen wirkungen von anthrachinon-medikamenten. | |
Klukowska et al. | Acquired factor VIII inhibitor in a non‐haemophilic boy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E601 | Decision to refuse application |